RGS 0.00% 12.0¢ regeneus ltd

Love them apples! Licence represents inflection point which will...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. TDA
    10,917 Posts.
    lightbulb Created with Sketch. 69
    Love them apples!

    Licence represents inflection point which will drive growth in long term shareholder value

    • Significant progress made towards finalising terms and conditions to secure Regeneus’ first clinical partner for Progenza in Japan
    • Management anticipates the partnership to be secured and details of this collaboration will be announced this quarter
    • This clinical collaboration will be an inflexion point for Regeneus, complementing the existing manufacturing relationship and commercial venture with AGC and positioning the company in Japan to grow long-term shareholder value
    • Collaboration will provide a foundation for new collaborations in other key markets
 
watchlist Created with Sketch. Add RGS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.